Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Mar 2021  |  Report ID: GMI4967  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 150   |   Base Year: 2020

Summary Table of Contents Industry Coverage Methodology

Industry trends

Anticoagulants Market size was valued at more than USD 32.2 billion in 2020 and is estimated to grow at CAGR of 6.4% between 2021 and 2027. Increasing prevalence of chronic diseases such as deep vein thrombosis and atrial fibrillation among others across the world will positively influence the market growth during forecast period.

Anticoagulants Market Research Report

Get more details on this report - Request Free Sample PDF

Anticoagulants are commonly known as blood thinners. The agents are chemical substances that reduce or prevent coagulation of blood. They are used before the surgery to reduce the risk of clots in veins, arteries and lungs. Also, anticoagulants are widely used clinically in cardiac surgeries, dialysis and deep vein thrombosis. Certain factors that are driving the market expansion include rising demand for anticoagulant products and increasing patient pool suffering from chronic illness.

The nationwide lockdowns across several countries to curb the spread of coronavirus have severely hampered the supply system. To overcome such shortcomings, competitors are coordinating with government agencies and seeking majorly e-commerce channels to supply. Thus, the COVID-19 pandemic had minimal impact on the anticoagulants market revenue. However, market players are focusing on development of novel products for blood clot treatment, thereby supplementing the industry growth. Also, major manufacturers of heparin have witnessed a decrease in their product sales, mainly due to influx of generic versions, thereby hampering the market demand to some extent.

Rise in number of patients suffering from coronary heart disease and myocardial infection will spur the anticoagulants market value

Coronary heart disease and myocardial infarction (MI) is considered as a critical and significant public health issue worldwide. There has been a noticeable rise in the number of patients suffering from coronary artery disease in U.S. According to the American Heart Association (AHA) report, nearly 1 in 7 deaths took place in U.S. owing to coronary heart disease in 2018. The report also stated that the prevalence of myocardial infection in adults is approximately 7.9 million (3%). This has led to a surge in demand for anticoagulant treatment, including surgical procedures. Such rising cases of chronic illness in both geriatric as well as middle aged population will further augment the industry expansion.

Side effect associated with anticoagulants may impede the market progression

Side effects associated with anticoagulants may hinder the growth of global anticoagulants market during the forecast timeline. Heparin-induced thrombocytopenia programs the body’s immune system to develop antibodies against its own platelets, causing the risk of bleeding. For instance, FDA receives around 450,000 adverse drug events every year, of which, around 3.8% were related to heparin, thereby hampering the market revenue. Also, warfarin causes various side effects such as chrondrodysplasia punctata, asplenia and foetal abnormalities. Such side effects will hamper the industry value. Although, prominent market leaders are trying to develop innovative products, but side effects may adversely affect their adoption rate.

Advantages associated with factor Xa inhibitor anticoagulants will impel the market demand

Anticoagulants Market Size

Get more details on this report - Request Free Sample PDF

The factor Xa inhibitor segment in the anticoagulants market accounted for USD 19.8 billion in 2020. Usage of factor Xa inhibitor drugs in patients with atrial fibrillation and DVT will boost the segment growth. The factor Xa inhibitors are a type of anticoagulants that work by selectively and reversibly blocking the activity of clotting factor Xa. This helps in preventing clot formation, thereby increasing the demand for such products. Also, they affect both factor Xa within the blood and within a pre-existing clot.

Injectable anticoagulants are used with caution with antiplatelet inhibitor to inhibit the thrombus

The anticoagulants market for injectable segment exceeded USD 19 billion in 2020. The most commonly used injectable anticoagulants are low molecular weight heparin, lepirudin, danaparoid, among others. The pharmacokinetic characteristics of these drugs have few interactions with food, predictable dose responses, and rapid onset and offset, thus resulting in simplified management of the patient requiring anticoagulant therapy. Also, due to the increased risk of bleeding, the injectable anticoagulants are used with caution with antiplatelet inhibitor, as they decrease platelet aggregation and inhibit thrombus formation. Thus, usage of these injectables for various disease treatments will fuel the segment expansion.

Increasing mortality rates of coronary heart disease in emerging economies will foster the segment revenue

The coronary heart disease application in the anticoagulants market accounted for USD 18.7 billion in 2020. Arterial thrombosis is caused when an artery is damaged by atherosclerosis. This may further lead to myocardial infraction and coronary artery disease, thereby augmenting the demand for anticoagulant drugs. Moreover, growing prevalence of coronary artery disease in the emerging economies will further propel the segment demand.

Patient preference for high quality care and ease of availability of medicine in hospital settings will upsurge the segment growth

Hospital pharmacy distribution channel dominated around 54% of the anticoagulants market share in 2020 and will showcase growth rate of 6% till 2027. Hospital pharmacy mainly monitors the supply of all medicines used in the hospital. Also, patients prefer hospital setting as they offer high quality care and ease of availability of medicines will further drive the segment share. Furthermore, increase in hospital admissions for surgeries and treatments will stimulate segment size in the forthcoming years.

 Rising prevalence of deep venous thromboembolism and pulmonary embolism will enhance the North America market growth 

North America Anticoagulants Market

Get more details on this report - Request Free Sample PDF

North America anticoagulants market accounted for USD 20.1 billion in 2020 owing to increasing prevalence of deep venous thromboembolism and pulmonary embolism in the region. According to the Centers for Disease Control and Prevention (CDC), approximately 60,000 to 100,000 individuals die from DVT/PE every year in the U.S. Also, the report stated that nearly 5% to 8% of the U.S. population has one of several genetic risk factors including inherited thrombophilia that increases the risk for thrombosis. This has led to an increase in anticoagulants demand for various disease treatment, thereby fostering the market expansion.

Adoption of various business strategies will provide new growth avenues for companies operating in the market

Notable companies operating in the anticoagulants market include Bristol-Myers Sqiubb, Amphastar Pharmaceutical, Sanofi, Hepalink group, Pfizer, Leo Pharma, Laboratories Farmaceuticos Rovi SA among others. Geographical expansion, product launch & approval and partnerships are the most commonly adopted business strategies to sustain market competition.

Some of the recent industry developments:

  • In December 2020, NATCO Pharma launched rivaroxaban molecule under the brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. This strategy is expected to add value to their existing portfolio, thereby strengthening its market position.
  • In August 2018, Fresenius Kabi launched heparin sodium in ready-to-administer freeflex containers. This launch has enabled company to expand their critical care portfolio.

The anticoagulants market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Drug Class

  • Factor Xa Inhibitor
  • Heparin
  • Warfarin
  • Direct thrombin inhibitors (DTIs)
  • Others

Market, By Route of Administration

  • Oral
  • Injectable

Market, By Application

  • Venous thromboembolism
  • Atrial fibrillation/flutter
  • Coronary artery disease
  • Others

Market, By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Frequently Asked Questions (FAQ) :

The market for anticoagulants was valued at over USD 32.2 billion in 2020 and will grow at a healthy CAGR of 6.4% between 2021-2027 owing to rising incidences of chronic diseases.
The industry value from the factor Xa inhibitor segment stood at USD 19.8 billion in 2020 and will expand due to its rising usage in patients with DVT and atrial fibrillation.
The market share from the hospital pharmacy distribution channel was pegged at around 54% in 2020 and is forecast to grow at a robust CAGR of 6% through 2027 owing to the easy availability of medicine and high-quality care.
North America anticoagulants market value stood at USD 20.1 billion in 2020 and will thrive with rising prevalence of pulmonary embolism and deep venous thromboembolism.

Premium Report Details

  • Published Date: Mar 2021
  • Pages: 150
  • Tables: 229
  • Charts / Figures: 18
  • Companies covered: 13

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X